Výsledky vyhledávání - "Joerg, Buchmann"

Abstract P4-07-15: Tumor infiltrating lymphocytes as a prognostic factor

Autor: Kathleen Schüler, Daniel Bethmann, Tilmann Lantzsch, Christoph Uleer, Volker Hanf, Susanne Peschel, Jutta John, Marleen Pöhler, Joerg Buchmann, Karl-Friedrich Buerrig, Edith Weigert, Eva Johanna Kantelhardt, Christoph Thomssen, Martina Vetter

Publikováno v: Cancer Research. 82:P4-07

Introduction. Tumor cells are influenced by their microenvironment, including immune infiltration. These tumor infiltrating lymphocytes (TILs) are considered to have prognostic and predictive value for patients with early breast cancer. The aim of th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fb60eec743febf564047f37a0f5b908c
https://doi.org/10.1158/1538-7445.sabcs21-p4-07-15

Zobrazit plný text záznamu

Abstract P4-06-13: Prospective analysis of molecular subtypes in triple negative breast cancer

Autor: Karl-Friedrich Buerrig, Jutta John, Martina Vetter, Christoph Thomssen, Volker Hanf, Carolin Hartung, Edith Weigert, Christoph Uleer, EJ Kantelhardt, Joerg Buchmann, Susanne Peschel, T Lantzsch

Publikováno v: Cancer Research. 80:P4-06

Introduction: Triple negative breast cancer (TNBC) is, in general, associated with unfavorable prognosis. However, TNBC it is a heterogenous disease. Thus, we analyzed the prognosis (RFI, OS) of TNBC in association to the molecular subtypes (accordin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9cd234b72918f524436beafd5b4d9d22
https://doi.org/10.1158/1538-7445.sabcs19-p4-06-13

Zobrazit plný text záznamu

Abstract P2-05-12: The ASCO-recommended prognostic factors uPA/PAI-1 in a multicenter cohort study (PiA)

Autor: Jutta John, Edith Weigert, Volker Hanf, C. Thomssen, Christoph Uleer, Carolin Hartung, T Lantzsch, Susanne Peschel, K-F Bürrig, EJ Kantelhardt, Martina Vetter, Joerg Buchmann

Publikováno v: Cancer Research. 77:P2-05

Introduction The PiA-study (Prognostic assessment in routine Application, NCT 01592825) was designed as a representative cohort of breast cancer patients to estimate the proportions of traditional and modern prognostic factors. The ASCO-recommended b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::49a09a1f11a2cc767badcb1d155b5659
https://doi.org/10.1158/1538-7445.sabcs16-p2-05-12

Zobrazit plný text záznamu

Abstract P2-08-22: The ASCO-recommended biomarkers urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 define a subgroup of patients with very low risk of recurrence under routine conditions

Autor: Claudia Wickenhauser, C. Thomssen, Nancy Papendick, Regina Grosse, S Steer, Martina Vetter, E-J Kantelhardt, Joerg Buchmann

Publikováno v: Cancer Research. 76:P2-08

Background: ASCO Tumor Marker Guidelines 2007 recommended clinical routine use of the invasion markers uPA and PAI-1 for risk assessment in node-negative breast cancer patients (Harris et al. JCO 2007; 25:5287), and in some countries, e.g. Germany an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::124cb22986671933dfacf376ee39b5e1
https://doi.org/10.1158/1538-7445.sabcs15-p2-08-22

Zobrazit plný text záznamu

Abstract P4-03-01: Vacuum assisted core-needle biopsy after neoadjuvant therapy in breast cancer to predict the status of pathologic response

Autor: Antonia Lebioda, R Große, Christine Fathke, Joerg Buchmann, Tin Dao Nguyen, Holger Zentgraf, Christoph Thomssen, S Steer, Jana Saegenschnitter

Publikováno v: Cancer Research. 80:P4-03

Introduction: Neoadjuvant breast cancer therapy trials have documented impressive rates of pathologic complete response (pCR) of up to 70% and above, depending on grade, hormone receptor and HER2 receptor status and type of therapy. The purpose of ou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::945220b3e8e555715152e33b1abb23c1
https://doi.org/10.1158/1538-7445.sabcs19-p4-03-01

Zobrazit plný text záznamu

Abstract P3-11-12: Vacuum assisted core-needle biopsy after neoadjuvant therapy in breast cancer to predict pathologic response

Autor: Christoph Thomssen, Jana Saegenschnitter, Thi-Dao Nguyen, Regina Grosse, Susanne Unverzagt, Eva Johanna Kantelhardt, Joerg Buchmann, Nancy Papendick

Publikováno v: Cancer Research. 75:P3-11

Introduction: Recently published neoadjuvant breast cancer therapy trials have documented impressive pathologic complete response (pCR) rates of up to 50% and above, depending on grade, hormone receptor and HER2 status and type of therapy. The purpos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::edc610f439f5a3a6beb3360f0ab0b4e5
https://doi.org/10.1158/1538-7445.sabcs14-p3-11-12

Zobrazit plný text záznamu

Abstract P2-10-38: Prognostic factors uPA/PAI-1: measurement in core needle biopsies

Autor: EJ Kantelhardt, Hans-Jürgen Holzhausen, B. Landstorfer, K Ruschke, T Lantzsch, Joerg Buchmann, Martina Vetter, R Große, C. Thomssen

Publikováno v: Cancer Research. 72:P2-10

Background: The urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 are validated as prognostic factors at the highest level of evidence within the node-negative group of breast cancer patients (Harris L et al., JCO 2007; 25:5287). Usu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::53d9744573f0ecc734380186d39fe634
https://doi.org/10.1158/0008-5472.sabcs12-p2-10-38

Zobrazit plný text záznamu

CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status

Autor: Sibylle Schmager, Jens Kollmeier, Ludwig Fischer von Weikersthal, Christian Schumann, Wolfgang Schuette, Joerg Buchmann, Jan Stoehlmacher, Dirk Behringer

Publikováno v: Clinical lung cancer. 16(6)

Introduction The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients with stage IIIB to IV prim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a7a1d27d9e0d614487eb46e930434f2
https://pubmed.ncbi.nlm.nih.gov/26094080

Zobrazit plný text záznamu

Reliability and validity of needle biopsy evaluation of breast-abnormalities using the B-categorization--design and objectives of the Diagnosis Optimisation Study (DIOS)

Autor: Thomas Loening, Tilmann Lantzsch, Alexander Kluttig, Andrea Schmidt-Pokrzywniak, Thomas Decker, Pietro Trocchi, Hans-Juergen Holzhausen, Steffen Hauptmann, Andreas Stang, Christoph Thomssen, Joerg Buchmann, A. Heinig, Werner Boecker, Christiane Taege

Publikováno v: BMC Cancer
BMC Cancer, Vol 7, Iss 1, p 100 (2007)

Background The planned nationwide implementation of mammography screening 2007 in Germany will increase the occurrence of mammographically detected breast abnormalities. These abnormalities are normally evaluated by minimal invasive core biopsy. To m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b4a89532b83cafb5485a1589605205d
https://pubmed.ncbi.nlm.nih.gov/17570833

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání